The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population

Psychiatry and Clinical Neurosciences

Volumn 53, Issue 5, 1999, Pages 593-597

  Someya, Toshiyuki ^a   Suzuki, Yutaro ^a   Shimoda, Kazutaka ^b   Hirokane, Genta ^b   Morita, Sachiyo ^b   Yokono, Aya ^b   Inoue, Yoshimasa ^c   Takahashi, Saburo ^d  

^a NIIGATA UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c Pharmacokinetics   (Japan)

^d Saitama Kounan Hospital   (Japan)

Author keywords

Cytochrome P450 (CYP) 2D6; Genotype; Haloperidol; Plasma concentration; Reduced haloperidol

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; HALOPERIDOL; REDUCED HALOPERIDOL;

ADULT; AGED; ALLELISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG METABOLISM; GENOTYPE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; GENOTYPE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0032752546     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.1999.00611.x     Document Type: Article

References (27)

1. Gorrod JW, Fang J. On the metabolism of haloperidol. Xenobiotica 1993; 23: 495-508.
2. Inaba T, Kovacs J. Haloperidol reductase in human and guinea pig livers. Drug Metab. Dispos. 1989; 17: 330-333.
3. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol:involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br. J. Clin. Pharmacol. 1991; 31: 655-660.
4. Oida T, Terauchi Y, Yoshida K, Kagemoto A, Sekine Y. Use of antisera in the isolation of human specific conjugate of haloperidol. Xenobiotica 1989; 19: 781-793.
5. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450: Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos. 1985; 13: 443-448.
6. Gram L, Debruyne D, Caillard V et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br. J. Clin. Pharmacol. 1989; 27: 272-275.
7. Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 1992a; 14: 92-97.
8. Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers. Ther. Drug Monit. 1992b; 14: 261-264.
9. Young D, Midha KK, Fosseler MJ et al. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6. Eur. J. Clin. Pharmacol. 1993; 44: 433-438.
10. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by alle-specific PCR amplification. Lancet 1990; 336: 529-532.
11. Steen VM, Andreassen OA, Daly AK et al. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-223.
12. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist E, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 1994; 46: 452-459.
13. Suzuki A, Otani K, Mihara K et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997; 7: 415-418.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. The American Psychiatric Association, Washington, DC, 1994.
15. Hikida K, Inoue Y, Miyazaki T, Kojima N, Ohkura Y. Determination of bromperidol in serum by automated column-switching high performance liquid chromatography. J. Chromatogr. 1989; 495: 227-234.
16. Llerena A, Cobaleda J, Martinez C, Benitez J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur. J. Drug Metab. Pharmacokinet. 1996; 21: 129-138.
17. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 1993; 90: 11825-11829.
18. Panserat S, Mura C, Gerard N et al. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): Evidence for two major allozymes in extensive metabolizers. Hum. Genet. 1994; 94: 401-406.
19. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 1995; 274: 516-520.
20. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991; 10: 545-558.
21. Roch HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6: 441-447.
22. Usuki E, Pearce R, Parkinson A, Castagnol N. Studies on the conversion of haloperidol and its tetrahydropyridine dehaydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem. Res. Toxicol. 1996; 9: 800-806.
23. Daniel DG, Randolph C, Jaskiw G et al. Coadministration of fluvoxamine increases serum concentration of haloperidol. J. Clin. Psychopharmacol. 1994; 14: 340-343.
24. Kudo S, Odomi M. Involvement of human cytochrome P450, 3A4 in reduced haloperidol oxidation. Eur. J. Clin. Pharmacol. 1998; 54: 253-259.
25. Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell. Molec. Neurobiol. 1997; 17: 227-233.
26. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br. J. Clin. Pharmacol. 1997; 44: 557-564.
27. Someya T, Takahashi S, Shibasaki M, Inaba T, Cheung SW, Tang SW. Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients. Psychiatry Res. 1990; 31: 111-120.